Literature DB >> 15294289

Characterisation of bacterially expressed structural protein E2 of hepatitis C virus.

Maria S Yurkova1, Arvind H Patel, Alexey N Fedorov.   

Abstract

The E2 glycoprotein is a structural component of the hepatitis C virus (HCV) virion. It interacts with putative cellular receptors, elicits production of neutralising antibodies against the virus, and is involved in viral morphogenesis. The protein is considered as a major candidate for anti-HCV vaccine. Despite this, relatively little is known about this protein. Previous studies have focused on the antigenic and functional analysis of the glycosylated forms. This report describes expression of the ectodomain of E2 (recE2) in Escherichia coli cells, its purification, and initial characterisation of its structural and functional properties. It is demonstrated that the purified protein forms small soluble aggregates, which retain functional characteristics of its native counterpart, i.e., it interacts with a putative cellular receptor, CD81, and is recognised by both conformation-dependent and -independent anti-E2 monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294289     DOI: 10.1016/j.pep.2004.05.016

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  5 in total

1.  Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain.

Authors:  Jillian Whidby; Guaniri Mateu; Hannah Scarborough; Borries Demeler; Arash Grakoui; Joseph Marcotrigiano
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

2.  Recombinant hepatitis C virus-envelope protein 2 interactions with low-density lipoprotein/CD81 receptors.

Authors:  Ana Carolina Urbaczek; Valdecir Farias Ximenes; Ana Afonso; Wesley Cardoso Generoso; Camila Tita Nogueira; Aline Tansini; Luciana Teresa Dias Cappelini; Wilson Malagó Júnior; Flávio Henrique da Silva; Luiz Marcos da Fonseca; Paulo Inácio da Costa
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-05-26       Impact factor: 2.743

3.  Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.

Authors:  Reem R Al Olaby; Laurence Cocquerel; Adam Zemla; Laure Saas; Jean Dubuisson; Jost Vielmetter; Joseph Marcotrigiano; Abdul Ghafoor Khan; Felipe Vences Catalan; Alexander L Perryman; Joel S Freundlich; Stefano Forli; Shoshana Levy; Rod Balhorn; Hassan M Azzazy
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

4.  Versatile format of minichaperone-based protein fusion system.

Authors:  Maria S Yurkova; Olga A Sharapova; Vladimir A Zenin; Alexey N Fedorov
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

5.  Polymer Particles Bearing Recombinant LEL CD81 as Trapping Systems for Hepatitis C Virus.

Authors:  Dmitry Polyakov; Ekaterina Sinitsyna; Natalia Grudinina; Mariia Antipchik; Rodion Sakhabeev; Viktor Korzhikov-Vlakh; Mikhail Shavlovsky; Evgenia Korzhikova-Vlakh; Tatiana Tennikova
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.